Carbon ion therapy for small cell lung cancer took a step forward in October 2026, when Frontiers in Oncology published new clinical results. At a carbon ion cancer treatment center in Wuwei, Gansu Province, China, 39 patients with limited-stage small cell lung cancer received carbon ion radiotherapy together with chemotherapy. The study reported a 2-year local control rate of 91.2% and a median overall survival of 44 months. This treatment is still being studied, and these results come from a retrospective analysis at one center. This article summarizes the findings, an earlier Shanghai study, the eligibility criteria of a Japanese hospital, and the fees for patients from abroad. To find out whether your case can be reviewed, please use our consultation on eligibility and cost for carbon ion therapy.
Why is carbon ion therapy of interest for small cell lung cancer?
Small cell lung cancer tends to grow quickly. When the disease stays in one side of the chest and nearby lymph nodes, it is called limited stage; when it has spread further, it is called extensive stage. For limited-stage disease, the standard approach combines platinum and etoposide chemotherapy with chest radiotherapy. The cancer usually responds well to both drugs and radiation at first.
The difficulty is that the tumor often involves large lymph nodes in the middle of the chest. The esophagus, heart, spinal cord and healthy lung sit right next to it, which limits how much radiation can be given safely. A carbon ion beam releases most of its energy at a set depth and then stops. This lets doctors concentrate a high dose in the tumor while sparing the organs behind it, and carbon ions also kill cancer cells more effectively than X-rays at the same dose. See What is carbon ion therapy? for the basics.
Carbon ion centers in China and Japan are now extending their experience with non-small cell lung cancer to small cell lung cancer. Results for non-small cell lung cancer are covered in carbon ion therapy for stage III lung cancer and carbon ion therapy for stage I lung cancer.
What did the 2026 carbon ion center study find?
The study was published by the Radiation Therapy Center of Gansu Wuwei Tumour Hospital and Gansu University of Chinese Medicine. It analyzed 39 patients with limited-stage small cell lung cancer treated at the center from June 2020. The median age was 61, 79.5% were men, and most had stage III disease. The visible tumor received 72 Gy (RBE) in 12 fractions, while lymph node regions at risk received 48 Gy (RBE) in the same sessions (simultaneous integrated boost). Platinum and etoposide chemotherapy was given at the same time or in sequence.
| Outcome | 1 year | 2 years | Median |
|---|---|---|---|
| Local control | 91.2% | 91.2% | - |
| Overall survival | 91.65% | 62.45% | 44 months |
| Progression-free survival | 72.00% | 47.77% | 24 months |
| Objective response at 3 months | 64.10% (25 of 39) | ||
The most notable result is that 91.2% of treated tumors remained controlled at 2 years. Radiation-related effects (esophagitis, pneumonitis, throat swelling) occurred in 30.8% of patients and were all grade 1–2. Low blood counts occurred in 66.7%, mostly attributed to chemotherapy; grade 3 was 7.7% and grade 4 was 5.1%, managed with blood tests and drug adjustment. Patients in better general condition (higher KPS score) lived longer.
The authors concluded that carbon ion therapy achieved good local control with low acute toxicity and can serve as an alternative treatment option for limited-stage small cell lung cancer. Because the data come from 39 patients at one center, larger studies are planned.
What about the Shanghai proton plus carbon ion study?
In 2021, researchers at the Shanghai Proton and Heavy Ion Center (SPHIC) and Fudan University Cancer Hospital reported a different approach in the same journal. Twenty-five patients with limited-stage small cell lung cancer first received protons to a wider area and then a carbon ion boost to the tumor. All patients received induction chemotherapy.
| Item | Details |
|---|---|
| Proton beam | 20–23 fractions, median 44 Gy (RBE) |
| Carbon ion boost | 5–8 fractions, median 23.1 Gy (RBE) |
| 1- and 2-year overall survival | 95.8% and 81.7% |
| 1- and 2-year progression-free survival | 79.0% and 41.2% (median 18.4 months) |
| Acute side effects | No grade 4 or higher; grade 3 in 20% (mostly low blood counts) |
With a median follow-up of 19.2 months, 2-year overall survival reached 81.7%. The authors described the survival and tolerability as promising and proposed a prospective trial. Differences between the two beams are explained in carbon ion vs proton therapy.
Who can ask for a review?
QST Hospital (National Institutes for Quantum Science and Technology, Chiba, Japan) lists the following lung conditions for carbon ion therapy. Small cell lung cancer is not named separately, so doctors judge each case based on stage, lymph node extent and response to chemotherapy.
| QST Hospital category | Stage criteria | Schedule |
|---|---|---|
| Lung cancer without metastasis or invasion of nearby organs | Tis, T1–T4N0 (excluding T4 by organ invasion) | Usually 1 day; about 3 weeks if a vital organ is close |
| Non-small cell lung cancer with lymph node spread | Tany N1–N3M0 or T4N0M0; no pleural or pericardial effusion | 16 fractions (about 4 weeks) |
| Lung metastases | 3 or fewer, primary treated, no spread outside the lungs | Decided case by case |
For small cell lung cancer, the key points are whether the disease is limited stage, how well it responded to chemotherapy, whether there is any spread outside the chest, and whether the chest has been irradiated before. These answers decide which carbon ion center in Japan or abroad is suitable. General criteria are covered in who can receive carbon ion therapy.
- Contrast chest CT and PET-CT images from the last 1–2 months (DICOM)
- Brain MRI results (to check for brain metastases)
- Pathology report (English translation recommended)
- Chemotherapy names, number of cycles, and images before and after
- Lung function tests and blood tests (blood counts, tumor markers NSE and ProGRP)
How to collect these is explained in carbon ion therapy documents checklist.
What does treatment in Japan cost for patients from abroad?
Patients from abroad are not covered by Japanese health insurance and pay privately. QST Hospital publishes the following fees on its page for patients from abroad (updated May 27, 2026).
| Item | QST Hospital published fee | Notes |
|---|---|---|
| Carbon ion radiotherapy | 5.786 million yen (tax included) | Self-pay for patients from abroad |
| Hospital stay, consultations, tests | 33 yen per medical fee point (tax included) | Depends on tests and admission |
| Medical coordinator fee | Not included | Varies by provider |
| Flights, lodging, interpreting | Not included | Depends on length of stay |
QST Hospital asks patients to contact it through a registered guarantor such as a medical coordinator or travel agency. A physician reviews the records and makes the final decision; if the case is suitable, preparation starts soon. After preparation there is a free period of about 1–2 weeks before treatment begins, and patients who go home must return by the day before treatment. Fees at other Japanese centers are compared in carbon ion therapy cost in Japan, and contact points are listed in Japanese medical institutions.
In small cell lung cancer, timing radiation with chemotherapy matters. Please check first through our consultation whether a review is possible at your current stage of treatment.
Frequently asked questions
Can small cell lung cancer be treated with carbon ion therapy?
At a Chinese carbon ion center, patients with limited-stage small cell lung cancer received carbon ions with chemotherapy, and a 2-year local control rate of 91.2% was reported. Japanese centers judge each case by stage and response to chemotherapy.
Can extensive-stage patients ask for a review?
Both studies in this article included limited-stage patients. Extensive-stage disease is treated mainly with drugs, and doctors decide whether to add radiation to remaining lesions after seeing the drug response.
Is it given with chemotherapy?
Both studies used platinum and etoposide chemotherapy. Whether to give them at the same time or in sequence depends on the patient's condition.
What are the side effects?
In the Wuwei study, all radiation-related effects were grade 1–2. Low blood counts were mainly due to chemotherapy and were managed with regular blood tests and drug adjustment.
How much does carbon ion therapy in Japan cost?
At QST Hospital, carbon ion radiotherapy for patients from abroad costs 5.786 million yen (tax included, page updated May 27, 2026). Hospital stay and tests are charged separately at 33 yen per point. Flights, lodging and coordinator fees are extra.
Related articles
Wondering if carbon ion therapy is possible for you, and what it costs?
We help you prepare consultations with Japanese institutions and provide medical interpreting.
Free consultationCall +82-2-517-5117Sources
- Liang X et al. Survival and prognostic factors analysis of carbon ion radiotherapy for limited-stage small cell lung cancer. Front Oncol 2026;16
- Ma NY et al. Preliminary Safety and Efficacy of Proton Plus Carbon-Ion Radiotherapy With Concurrent Chemotherapy in Limited-Stage Small Cell Lung Cancer. Front Oncol 2021;11:766822
- QST Hospital — Indications: lung cancer
- QST Hospital — For Patients from Abroad (fees, procedure; updated 2026-05-27)
General information based on public sources; not a substitute for diagnosis or treatment. Eligibility is decided by the treating physicians. Written by the FTH editorial team.